NEW YORK (TheStreet) -- CHANGE IN RATINGS
Cigna (CI) upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $56 price target. New analyst also placed the company on the US Focus List. Company can continue to grow the business and return capital to shareholders. $56 price target.
Cepheid (CPHD) rated new Hold at Cantor. Valuation call, based on a $40 price target.
Equifax (EFX) rated new Hold at Deutsche Bank. Valuation call, based on a $47 price target.Humana (HUM) downgraded at Credit Suisse from Outperform to Neutral, Credit Suisse said. $74 price target. New analyst has a $74 price target. Louisiana-Pacific (LPX) upgraded at BofA/Merrill from Underperform to Buy, Bank of America/Merrill Lynch said. Valuation call, based on a $16 price target. Louisiana-Pacific downgraded at Deutsche. LPX was downgraded from Buy to Hold, Deutsche Bank said. Valuation call, based on a $12 price target. Pandora (P) upgraded at Canaccord from Hold to Buy, Canaccord Genuity said. Visibility is improving. $16 price target. Rowan (RDC) rated new Outperform at Credit Suisse. RDC was initiated with an Outperform rating, Credit Suisse said. $50 price target. Company was also placed on the Focus List. Company trades at a discount to its peers. Vertex Pharmaceuticals (VRTX) rated new Buy at ThinkEquity. $64 price target. Kalydeco should drive near-term growth.
STOCK COMMENTS / EPS CHANGESBrown Forman (BF.B) numbers raised at UBS. Shares of BF.b now seen reaching $72, UBS said. Estimates also increased on positive outlook. Buy rating. HJ Heinz (HNZ) numbers reduced at Credit Suisse. HNZ estimates were cut through 2015, Credit Suisse said. Company is seeing lower operating earnings. Neutral rating and new $57 price target. Joy Global (JOY) numbers lowered at Jefferies. Shares of JOY now seen reaching $50, Jefferies said. Estimates also lowered on poor revenue outlook. Hold rating. Pandora (P) estimates, target raised at Credit Suisse. Shares of P now seen reaching $13, according to Credit Suisse. Estimates also increased, as the company is realizing higher operating leverage. Neutral rating.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV